Biotechnology company Celyad Oncology (Euronext Brussels:CYAD) announced on Thursday that it has sold its C-Cathez transendocardial catheter to CellProthera, including all intellectual property rights and technical documentation.
The catheter will serve as a core component in CellProthera's upcoming Phase 3 clinical trial, enabling targeted stem cell delivery to damaged cardiac tissue.
The agreement provides for up to EUR5m in milestone-based payments and future royalties on net sales. As the consideration is fully deferred, the transaction will not affect Celyad Oncology's current cash runway, which is expected to last through the third quarter of 2026.
CellProthera is a regenerative cell therapy developer specializing in ischemic diseases, with a leading program in myocardial infarction.
Aptamer Optimer technology integrated into Twist Bioscience TrueAmp Library Preparation Kit
AsymBio builds integrated platforms across biopharmaceutical development lifecycle
Evogene expands Google Cloud collaboration to integrate AI agents into ChemPass AI
Cumulus Neuroscience enters Japanese market with Shionogi collaboration
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
CiteAb launches new scientific image search tool and improved reagent search engine
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
BioArctic and Eisai secure Priority Review in China for subcutaneous Leqembi
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Delonix Bioworks gets IND clearance for DX-104 in China
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288